Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$38.36 +5.3%	$33.93	$21.62 ▼ $39.54	$7.28B	1.08	2.33 million shs	10.83 million shs
CNTA Centessa Pharmaceuticals	$13.71 -0.1%	$14.26	$7.75 ▼ $19.09	$1.83B	1.53	610,862 shs	553,595 shs
LNTH Lantheus	$104.34 +0.4%	$98.78	$65.89 ▼ $126.89	$7.15B	0.2	951,195 shs	687,273 shs
TGTX TG Therapeutics	$45.51 +3.8%	$37.95	$14.87 ▼ $45.83	$7.23B	2.14	3.07 million shs	3.27 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+5.33%	+8.70%	+10.96%	+6.64%	+49.73%
CNTA Centessa Pharmaceuticals	-0.07%	+5.22%	-4.66%	-18.92%	+49.67%
LNTH Lantheus	+0.37%	+3.10%	+6.91%	+12.45%	+56.81%
TGTX TG Therapeutics	+3.76%	+15.09%	+15.42%	+36.42%	+233.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5442 of 5 stars	4.5	1.0	3.9	2.7	4.2	0.6
CNTA Centessa Pharmaceuticals	2.5563 of 5 stars	3.5	1.0	0.0	2.9	3.3	0.6
LNTH Lantheus	3.98 of 5 stars	2.5	1.0	4.2	3.5	2.5	1.9
TGTX TG Therapeutics	3.3352 of 5 stars	1.4	3.0	3.5	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	48.83% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.71	102.15% Upside
LNTH Lantheus	3.00	Buy	$129.43	24.05% Upside
TGTX TG Therapeutics	2.83	Moderate Buy	$40.67	-10.64% Downside

Current Analyst Ratings Breakdown

Latest CNTA, LNTH, BBIO, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00
3/31/2025	BBIO BridgeBio Pharma	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/24/2025	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $50.00
3/21/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $122.00
3/7/2025	CNTA Centessa Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$27.00 ➝ $27.00
3/4/2025	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	32.82	N/A	N/A	($7.71) per share	-4.98
CNTA Centessa Pharmaceuticals	$6.85M	266.45	N/A	N/A	$2.42 per share	5.67
LNTH Lantheus	$1.53B	4.66	$8.71 per share	11.98	$11.91 per share	8.76
TGTX TG Therapeutics	$329.00M	21.96	$0.13 per share	353.90	$1.06 per share	42.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$2.85	N/A	N/A	N/A	-241.44%	N/A	-75.69%	N/A
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.99	N/A	N/A	N/A	N/A	-52.13%	-38.01%	5/12/2025 (Estimated)
LNTH Lantheus	$326.66M	$4.37	17.36	16.54	N/A	28.57%	44.29%	23.52%	5/7/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.14	N/A	45.51	N/A	-5.42%	-8.32%	-3.40%	5/7/2025 (Estimated)

Latest CNTA, LNTH, BBIO, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	N/A	N/A	N/A	$377.37 million	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	N/A	N/A	N/A	$117.07 million	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million
2/27/2025	Q4 2024	LNTH Lantheus	$1.57	$1.34	-$0.23	-$0.17	$376.61 million	$391.11 million
2/20/2025	Q4 2024	BBIO BridgeBio Pharma	-$1.09	-$1.31	-$0.22	-$1.40	$4.04 million	$5.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
LNTH Lantheus	N/A	1.65	1.56
TGTX TG Therapeutics	1.27	4.59	3.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
CNTA Centessa Pharmaceuticals	82.01%
LNTH Lantheus	99.06%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	24.66%
CNTA Centessa Pharmaceuticals	11.59%
LNTH Lantheus	1.50%
TGTX TG Therapeutics	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.86 million	143.29 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.18 million	116.56 million	Optionable
LNTH Lantheus	700	68.48 million	68.48 million	Optionable
TGTX TG Therapeutics	290	158.78 million	139.32 million	Optionable

CNTA, LNTH, BBIO, and TGTX Headlines

Recent News About These Companies

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

April 30 at 11:05 AM | zacks.com

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

April 30 at 7:30 AM | globenewswire.com

Boothbay Fund Management LLC Invests $2.57 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 30 at 6:22 AM | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings

April 29 at 12:47 PM | finance.yahoo.com

Artia Global Partners LP Invests $1.64 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 29 at 7:00 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Lessened by Virtus ETF Advisers LLC

April 29 at 6:23 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Gilder Gagnon Howe & Co. LLC

April 29 at 6:15 AM | marketbeat.com

Syon Capital LLC Buys New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 28 at 5:36 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Tower Research Capital LLC TRC

April 28 at 4:44 AM | marketbeat.com

Commerce Bank Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 27, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Consensus Target Price from Analysts

April 27, 2025 | americanbankingnews.com

Penn Capital Management Company LLC Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 26, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

April 26, 2025 | marketbeat.com

Hood River Capital Management LLC Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Barclays PLC

April 25, 2025 | marketbeat.com

Guggenheim Capital LLC Sells 14,905 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 24, 2025 | marketbeat.com

481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.

April 23, 2025 | marketbeat.com

Russell Investments Group Ltd. Purchases 26,506 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 23, 2025 | marketbeat.com

TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough

April 23, 2025 | seekingalpha.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by MYDA Advisors LLC

April 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA, LNTH, BBIO, and TGTX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$38.36 +1.94 (+5.33%)

As of 04/30/2025 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.71 -0.01 (-0.07%)

As of 04/30/2025 04:00 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Lantheus NASDAQ:LNTH

$104.34 +0.38 (+0.37%)

As of 04/30/2025 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$45.51 +1.65 (+3.76%)

As of 04/30/2025 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time